FY2020 Drug Pricing Reform

• Drug Pricing Debate for 2020 Reform Going into High Gear; Industry Leery of Post-Election Surprises
  July 5, 2019

• Revisit Comparator Selection Criteria for New Drug Pricing: JPMA
  June 28, 2019

• Chuikyo Raises No Objection to Earlier Price Cuts for LLPs, Payers Want Stricter Rule
  June 27, 2019

• Set Lower Premiums for Super Pricey Cell, Gene Therapies: Drug Pricing Organization
  June 26, 2019

• Drug Pricing Organization Pitches Earlier Price Cuts for LLPs If AGs Launched, PMP Tweaks and More
  June 26, 2019

• Generic Share Hits Plateau after Reaching 70%: FPMAJ Pharmacy Survey
  June 17, 2019

• Don’t Expand Comparator PMP Removal Rule, Set Deduction Limit for Method II: FPMAJ
  June 17, 2019

• Discuss Cost Effectiveness Assessment, Disclosure Ratios Separately: FPMAJ
  June 17, 2019

• FPMAJ Calls for Post-Launch Premiums for Add’l Indications, Evidence
  June 17, 2019

• Fix Price Maintenance Premium to Make It Fit Its Concept, Revisit Product/Company Criteria: FPMAJ
  June 17, 2019

• Chuikyo Subcommittee Agrees on Discussion Timeline, Topics for 2020 Drug Pricing Reform
  May 30, 2019

• 87% of Drug Makers Say 2018 Pricing Reform Hit Their R&D, Businesses: MHLW Survey
  May 15, 2019

• Chuikyo Reps Want Early Debate for 2020 Drug Price Revision; Polypharmacy, Formulary Also on Agenda
  March 28, 2019

• Chuikyo OKs 70% Pricing for Nesp Biosame; New Rules Up for FY2020 Reform Debate
  March 28, 2019

• Chuikyo Approves Discussion Timeline for FY2020 Reimbursement Reform; Drug Pricing Debates Expected from June
  March 7, 2019

ページ